Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Medtronic
Merck
Argus Health
Mallinckrodt
US Army
US Department of Justice
Daiichi Sankyo
Julphar
Harvard Business School

Generated: November 14, 2018

DrugPatentWatch Database Preview

Liothyronine sodium - Generic Drug Details

« Back to Dashboard

What are the generic sources for liothyronine sodium and what is the scope of liothyronine sodium patent protection?

Liothyronine sodium is the generic ingredient in three branded drugs marketed by X Gen Pharms, Par Sterile Products, King Pharms, Mayne Pharma Inc, Mylan, Sigmapharm Labs Llc, Sun Pharm Inds Ltd, and Watson Labs, and is included in nine NDAs. Additional information is available in the individual branded drug profile pages.

There are four drug master file entries for liothyronine sodium. Nineteen suppliers are listed for this compound.

Pharmacology for liothyronine sodium
Ingredient-typeTriiodothyronine
Drug Classl-Triiodothyronine
Synonyms for liothyronine sodium
3-[4-(4-Hydroxy-3-iodophenoxy)-3,5-diiodophenyl]-L-alanine Monosodium Salt
3,3 inverted exclamation marka,5-Triiodo-L-thyronine sodium salt
3,3',5-L-Triiodothyronine
3,3',5-Triiodo-L-thyronine (sodium)
3,3',5-Triiodo-L-thyronine sodium
3,3',5-Triiodo-L-thyronine sodium salt
3,3',5-Triiodo-L-thyronine sodium salt, >=95% (HPLC)
3,3',5-Triiodo-L-thyronine sodium salt, gamma-irradiated, powder, BioXtra, suitable for cell culture
3,3',5-Triiodo-L-thyronine sodium salt, powder, BioReagent, suitable for cell culture
3,3',5-Triiodo-L-thyronine, sodium salt
3,3',5-Triiodothyronine sodium salt
55-06-1
A830467
ACT03263
AK133067
AKOS015918421
AKOS032949712
Alanine, 3-(4-(4-hydroxy-3-iodophenoxy)-3,5-diiodophenyl)-, monosodium salt, L-
Alanine, 3-(4-(4-hydroxy-3-iodophenoxy)-3,5-diiodophenyl)-, monosodium salt, L- (8CI)
AS-13674
Basoprocin
BIT3090
C15H11I3NNaO4
C15H11I3NO4.Na
CAS-55-06-1
CC-12863
CCG-39522
CHEBI:6484
CHEMBL1201119
CS-3241
CT-834
Cynomel
Cyomel
Cytobin
Cytomel
Cytomel (TN)
Cytomel sodium
Cytomine
D01011
DSSTox_CID_27505
DSSTox_GSID_47505
DSSTox_RID_82385
DTXSID8047505
EINECS 200-223-5
EN300-221646
Epitope ID:136777
FT-0600822
GCA9VV7D2N
HMS1921H18
HMS2092B14
HY-A0070
I14-8106
I927
Ibiothyron
J10092
KS-00000UT3
L-3,3 inverted exclamation marka,5-Triiodothyronine, Sodium Salt
L-3,3',5-Triiodothyronine sodium salt
L-Triiodothyronine sodium salt
L-Tyrosine, O-(4-hydroxy-3-iodophenyl)-3,5-diiodo-, monosodium salt
Liothyronin sodium
Liothyronin sodium salt
Liothyronine for peak identification, European Pharmacopoeia (EP) Reference Standard
Liothyronine sodium (JP17/USAN)
Liothyronine sodium [USAN:BAN:JAN]
Liothyronine sodium salt
Liothyronine sodium, European Pharmacopoeia (EP) Reference Standard
Liothyroninesodium
LS-158302
LS41185
MFCD00002594
MLS000028648
MolPort-003-666-408
Monosodium L-3-(4-(4-hydroxy-3-iodophenoxy)-3,5-diiodophenyl)alanine
NCGC00256816-01
NRP-409
NSC 80774
O-(4-Hydroxy-3-iodophenyl)-3,5-diiodo-L-tyrosine sodium salt
O-(4-Hydroxy-3-iodophenyl)-3,5-diiodo-L-tyrosinesodium salt
Q-201881
Ro thyronine
s4217
SBXXSUDPJJJJLC-YDALLXLXSA-M
SC-94862
SCHEMBL41654
SMR000059206
sodium (2S)-2-amino-3-[4-(4-hydroxy-3-iodophenoxy)-3,5-diiodophenyl]propanoate
sodium (2S)-2-azanyl-3-[3,5-bis(iodanyl)-4-(3-iodanyl-4-oxidanyl-phenoxy)phenyl]propanoate
Sodium 3,3',5-triiodo-L-thyronine
Sodium 3,5,3'-triiodo-L-thyronine
Sodium 3,5,3'-triiodothyronine
Sodium L-3,5,3'-triiodothyronine
Sodium liothyronine
Sodium T3
Sodium Triiodo-L-thyronine
Sodium triiodothyronine
Sodium triiodothyronine, L-
Sodium triiodotironine
Sodium-L-triiodothyronine
sodium;(2S)-2-amino-3-[4-(4-hydroxy-3-iodophenoxy)-3,5-diiodophenyl]propanoate
SPECTRUM1502047
T-3
T3 sodium salt
Tertroxin
Tox21_302514
Triiodothyronine sodium
Triiodothyronine Sodium Salt
TRIIODOTHYRONINE SODIUM, LEVO
Triostat
Triostat (TN)
UNII-GCA9VV7D2N
UNII-YW8HJ0N26X component SBXXSUDPJJJJLC-YDALLXLXSA-M
ZX-AFC000843

US Patents and Regulatory Information for liothyronine sodium

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Par Sterile Products TRIOSTAT liothyronine sodium INJECTABLE;INJECTION 020105-001 Dec 31, 1991 AP RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Watson Labs LIOTHYRONINE SODIUM liothyronine sodium TABLET;ORAL 085755-001 Jan 25, 1982 DISCN No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Mayne Pharma Inc LIOTHYRONINE SODIUM liothyronine sodium TABLET;ORAL 090097-001 Mar 20, 2009 AB RX No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
King Pharms CYTOMEL liothyronine sodium TABLET;ORAL 010379-001 Approved Prior to Jan 1, 1982 AB RX Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Medtronic
Merck
Argus Health
Mallinckrodt
US Army
US Department of Justice
Daiichi Sankyo
Julphar
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.